What the FDA labels say about taking them together
Ethinyl estradiol/norelgestromin and sofosbuvir/velpatasvir/voxilaprevir
Ethinyl estradiol/norelgestromin's FDA label (Gwyn Lo) of July 6, 2026 names sofosbuvir/velpatasvir/voxilaprevir in its drug interactions section; the sofosbuvir/velpatasvir/voxilaprevir label PlainMeds reads does not name ethinyl estradiol/norelgestromin.
Check it at the source: the ethinyl estradiol/norelgestromin FDA label on DailyMed (effective April 16, 2026, Zydus Pharmaceuticals USA Inc.); the sofosbuvir/velpatasvir/voxilaprevir FDA label on DailyMed (effective July 14, 2025, Gilead Sciences, Inc.).
What does the ethinyl estradiol/norelgestromin label say about sofosbuvir/velpatasvir/voxilaprevir?
Gwyn Lo label (Viatris Specialty LLC, July 6, 2026), drug interactionsUse with Direct Acting Antiviral Agents (DAAs) – Liver Enzyme Elevation During clinical trials with the HCV combination drug regimen ombitasvir/paritaprevir/ritonavir and dasabuvir, with and or without ribavirin, or with glecaprevir/pibrentasvir or sofosbuvir/velpatasvir/voxilaprevir, ALT elevations were significantly more frequent in women using ethinyl estradiol-containing medicinal products such as CHCs [see Contraindications (4) and Warnings and Precautions (5.3) ].
Gwyn Lo label (Viatris Specialty LLC, July 6, 2026), warnings and precautionsAdditionally, similar ALT elevations were observed in women using ethinyl estradiol-containing medications such as CHCs when co-administered with Directly Acting Antivirals (DAA) that contains combination drug regimen with glecaprevir/pibrentasvir or sofosbuvir/velpatasvir/voxilaprevir.
Source: FDA drug label (Gwyn Lo, NDA219990), Viatris Specialty LLC, effective July 6, 2026 (SPL set e92741f4-87fe-429f-b5b5-c558ed5f4fa9), via openFDA
Source: FDA drug label (norelgestromin and ethinyl estradiol), Zydus Pharmaceuticals USA Inc., effective April 16, 2026 (SPL set 10fa1458-c8ed-4197-922a-1ba7271d2b02), via openFDA; the full label on DailyMed
What does the sofosbuvir/velpatasvir/voxilaprevir label say about ethinyl estradiol/norelgestromin?
Sofosbuvir/velpatasvir/voxilaprevir's label (effective July 14, 2025) does not name ethinyl estradiol/norelgestromin in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Vosevi), Gilead Sciences, Inc., effective July 14, 2025 (SPL set 17ffc094-8ca7-45d2-80d8-fd043bc9a221), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Ethinyl estradiol/norelgestromin | Sofosbuvir/velpatasvir/voxilaprevir | |
|---|---|---|
| Labeled for | Birth control | Hepatitis C |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $37.16 per patch 150-35 mcg/day patch | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once